FDA Launches Safety Review Of Asthma Drug Xolair

Law360, New York (July 16, 2009, 7:05 PM EDT) -- The U.S. Food and Drug Administration has announced that it is reviewing preliminary safety findings from an observational study that suggest asthma drug Xolair may be linked to an increased risk of cardiovascular problems and other adverse health issues.

The FDA said Wednesday that early findings from an observational study conducted by the two companies that jointly manufacture and distribute Xolair in the U.S. – Genentech Inc. and Novartis Pharmaceuticals Corp. – showed an increased number of heart- and brain-related health complications in study patients over...
To view the full article, register now.